Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.

Benzinga • Jul 24, 2026

Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Zacks Investment Research • Jul 24, 2026

American Express, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Benzinga • Jul 24, 2026

Edwards Lifesciences beats quarterly estimates on strong demand for heart devices

Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped ​by strong demand for its artificial heart ‌valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.

Reuters • Jul 23, 2026

Heart-Valve Maker Edwards Lifesciences Launches On Beat-And-Raise Second Quarter

Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.

Investors Business Daily • Jul 23, 2026

Edwards Lifesciences Q2 Earnings Call Highlights

Edwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.

MarketBeat • Jul 23, 2026

Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth

The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.

WSJ • Jul 23, 2026

Edwards Lifesciences Reports Second Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas.

Business Wire • Jul 23, 2026

Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript

Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 24, 2026

Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Jul 23, 2026